Pharmaceuticals News and Research

RSS

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

31 Aug 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),

31 Aug 2010

Unilife Corporation 2010 fourth quarter revenue increases to $2.7 million

Unilife Corporation today announced preliminary financial results for the fourth quarter and fiscal year ended June 30, 2010.

31 Aug 2010

Study: Explosion of medical imaging due partly to overuse

"Part of the explosion in medical imaging over the past two decades may be attributable to overuse, and steps need to be taken to cut back," according to a study in the journal Radiology, MedPage Today/ABC News reports.

30 Aug 2010

H. D. Smith becomes primary supplier of pharmaceutical products for NAPPSA pharmacies

NAPPSA, a pharmacy buying group advancing the growing buying power of the Nigerian-owned independent retailers, today announced a new three-year prime vendor agreement with H. D. Smith, a leading national pharmaceutical wholesaler.

30 Aug 2010

Opinions: MDG progress; Drug patents; Aid for scientific research; Avoiding food crises; Hunger in India; U.S. commitments to PEPFAR, Global Fund

"Between the catastrophes of the Haiti earthquake and the Pakistan floods, there was actually some good news this spring on the global health front, which offers hope that the United Nations' ambitious Millennium Development Goals might not be at a standstill. Though a great deal remains to be done, all of us are living longer, fewer mothers are dying in childbirth, and fewer children are dying before school age," Eli Adashi, professor of medical science at Brown University, writes in Boston Globe editorial.

30 Aug 2010

Also in Global Health News: GM mosquitoes; Iodine deficiency in Nepal; South African health workers strike; Novartis to build vaccine plant in Brazil; Population control in Niger

Malaysia is still "considering releasing" up to 3,000 mosquitoes that are genetically modified to "combat dengue fever, in a landmark field trial that has come in for criticism from environmentalists," Agence France-Presse reports. The insects are modified "so that their offspring quickly die," which researchers hope will cull the population and lessen the risk of dengue.

30 Aug 2010

HUYA announces strategic partnership with School of Pharmaceutical Sciences at Sun Yat-sen University

HUYA Bioscience International, a company at the forefront of globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU). The collaborative agreement expands HUYA's foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school's research efforts.

30 Aug 2010

Cannabis Science seeks entry into European medical cannabis market

Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges.

30 Aug 2010

Smoked cannabis relieves chronic neuropathic pain

The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which may not always be effective and may have unwanted side effects. A new study by McGill University Health Centre (MUHC) and McGill University researchers provides evidence that cannabis may offer relief to patients suffering from chronic neuropathic pain.

30 Aug 2010

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

30 Aug 2010

IriSys signs business alliance agreement with Xcelience

IriSys and Xcelience have entered into a business alliance agreement to advance the ability to streamline access to CMC and regulatory expertise for North American pharmaceutical and biotechnology companies.

30 Aug 2010

Meda signs agreement to acquire Alaven

Meda has signed an agreement to acquire the US specialty pharmaceutical company Alaven. The acquisition will significantly enhance Meda's marketing capabilities in the US and expand the therapeutic focus to include both gastroenterology and women's health; areas that Meda already operates in outside of the US.

30 Aug 2010

Pharmacists play major role in improving patients' health: Survey

A new international survey shows that over 90% of pharmacists believe they are key to improving patients' health, and while most pharmacists surveyed see their responsibilities increasing, they voice concerns on training and pay. The survey shows that almost 3 in 4 pharmacists (73%) now provide patients with health promotion and management services.

30 Aug 2010

China Pharmaceuticals 2010 second quarter net sales increase 105%

China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record financial results for its second quarter ended June 30, 2010.

30 Aug 2010

IntegriChain ranked #391 on Inc. 500 list of fastest growing private companies

IntegriChain, Inc., a leading provider of informatics and data enrichment services to the pharmaceutical industry was identified by Inc. 500 as #391 on the list of fastest growing private companies in America. Despite the general economic slowdown, IntegriChain's innovative approach to leveraging their customers' existing information assets has led to a three year growth rate of over 750%.

30 Aug 2010

Protalix common stock receives approval for Tel Aviv Stock Exchange listing

Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.

30 Aug 2010

Pharmaceuticals News and Research

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

FDA extends Prescription Drug User Fee Act date for ezogabine

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Unilife Corporation 2010 fourth quarter revenue increases to $2.7 million

Study: Explosion of medical imaging due partly to overuse

H. D. Smith becomes primary supplier of pharmaceutical products for NAPPSA pharmacies

Opinions: MDG progress; Drug patents; Aid for scientific research; Avoiding food crises; Hunger in India; U.S. commitments to PEPFAR, Global Fund

Also in Global Health News: GM mosquitoes; Iodine deficiency in Nepal; South African health workers strike; Novartis to build vaccine plant in Brazil; Population control in Niger

HUYA announces strategic partnership with School of Pharmaceutical Sciences at Sun Yat-sen University

Cannabis Science seeks entry into European medical cannabis market

Smoked cannabis relieves chronic neuropathic pain

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

IriSys signs business alliance agreement with Xcelience

Meda signs agreement to acquire Alaven

Pharmacists play major role in improving patients' health: Survey

China Pharmaceuticals 2010 second quarter net sales increase 105%

IntegriChain ranked #391 on Inc. 500 list of fastest growing private companies

Protalix common stock receives approval for Tel Aviv Stock Exchange listing

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence